CY1118200T1 - Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης - Google Patents

Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης

Info

Publication number
CY1118200T1
CY1118200T1 CY20161101131T CY161101131T CY1118200T1 CY 1118200 T1 CY1118200 T1 CY 1118200T1 CY 20161101131 T CY20161101131 T CY 20161101131T CY 161101131 T CY161101131 T CY 161101131T CY 1118200 T1 CY1118200 T1 CY 1118200T1
Authority
CY
Cyprus
Prior art keywords
treatment
polynucleotides
polypeptides
compositions
latent tuberculosis
Prior art date
Application number
CY20161101131T
Other languages
Greek (el)
English (en)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1118200T1 publication Critical patent/CY1118200T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CY20161101131T 2008-07-25 2016-11-04 Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης CY1118200T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (1)

Publication Number Publication Date
CY1118200T1 true CY1118200T1 (el) 2017-06-28

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101131T CY1118200T1 (el) 2008-07-25 2016-11-04 Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης

Country Status (24)

Country Link
US (2) US20110117119A1 (https=)
EP (1) EP2315773B1 (https=)
JP (1) JP5873332B2 (https=)
KR (1) KR20110044883A (https=)
CN (1) CN102164952B (https=)
AU (1) AU2009273130B2 (https=)
BR (1) BRPI0916703A2 (https=)
CA (1) CA2731499C (https=)
CO (1) CO6341637A2 (https=)
CY (1) CY1118200T1 (https=)
DK (1) DK2315773T3 (https=)
EA (1) EA024826B1 (https=)
ES (1) ES2602430T3 (https=)
HR (1) HRP20161458T1 (https=)
HU (1) HUE031044T2 (https=)
IL (1) IL210559A0 (https=)
LT (1) LT2315773T (https=)
MX (1) MX2011000983A (https=)
PL (1) PL2315773T3 (https=)
PT (1) PT2315773T (https=)
SG (1) SG192456A1 (https=)
SI (1) SI2315773T1 (https=)
UA (1) UA107330C2 (https=)
WO (1) WO2010010177A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1144447T3 (da) * 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
CA2731549C (en) 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
MX2011011186A (es) 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
BR112016006284B1 (pt) 2013-09-27 2022-07-26 Codexis, Inc Método implementado por computador, produto de programa de computador, e, sistema de computador
RU2016116253A (ru) 2013-09-27 2017-11-01 Кодексис, Инк. Автоматизированный скрининг вариантов фермента
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
PL202844B1 (pl) * 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
NZ526807A (en) * 2001-01-08 2005-03-24 Isis Innovation Assay to determine efficacy of treatment for mycobacterial infection
US20040121322A9 (en) * 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
BRPI0612833A2 (pt) * 2005-06-23 2010-11-30 Statens Seruminstitut composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
MX2011011186A (es) * 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.

Also Published As

Publication number Publication date
UA107330C2 (uk) 2014-12-25
AU2009273130A1 (en) 2010-01-28
SI2315773T1 (sl) 2016-12-30
CO6341637A2 (es) 2011-11-21
PL2315773T3 (pl) 2017-07-31
EP2315773A1 (en) 2011-05-04
US20140178423A1 (en) 2014-06-26
HUE031044T2 (en) 2017-06-28
EP2315773B1 (en) 2016-08-24
JP2011528895A (ja) 2011-12-01
LT2315773T (lt) 2016-11-10
DK2315773T3 (en) 2016-12-12
CN102164952A (zh) 2011-08-24
US9795663B2 (en) 2017-10-24
BRPI0916703A2 (pt) 2019-12-24
CA2731499A1 (en) 2010-01-28
EA201100072A1 (ru) 2011-10-31
ES2602430T3 (es) 2017-02-21
SG192456A1 (en) 2013-08-30
US20110117119A1 (en) 2011-05-19
WO2010010177A1 (en) 2010-01-28
AU2009273130B2 (en) 2014-10-16
CN102164952B (zh) 2016-05-25
HRP20161458T1 (hr) 2016-12-16
JP5873332B2 (ja) 2016-03-01
IL210559A0 (en) 2011-03-31
CA2731499C (en) 2017-01-10
EA024826B1 (ru) 2016-10-31
KR20110044883A (ko) 2011-05-02
PT2315773T (pt) 2016-11-23
MX2011000983A (es) 2011-03-02

Similar Documents

Publication Publication Date Title
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
CY1119789T1 (el) Cgrp αντισωματα
CY1121687T1 (el) Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων
CY1122564T1 (el) Μορια δεσμευσης μονhς αλυσιδας που περιλαμβανουν ν-τελικο αβρ
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1107042T1 (el) Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων
EA201171494A1 (ru) Миметики белка smac
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
CY1121455T1 (el) Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
CY1117697T1 (el) Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
ECSP12012272A (es) Proteínas que se unen al tnf-?
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης